Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

What is the rationale for using ASA404 in combination with docetaxel for lung cancer treatment?

April 26, 2017asa404 combination docetaxel lung cancer rationale treatment

0

Posted

What is the rationale for using ASA404 in combination with docetaxel for lung cancer treatment?

1 Answer

0

Posted

ASA404 plus docetaxel has the potential to improve the secondline treatment of patients with advanced non-small cell lung cancer (NSCLC). Docetaxel alone has been demonstrated to increase overall survival in patients with advanced NSCLC following first-line platinum-based therapy and is approved worldwide for this indication. The antitumor effect of ASA404 has been shown to increase synergistically when combined with taxanes. It is thought that synergistic tumor cell killing occurs as ASA404 acts on poorly perfused regions of the tumor that are inaccessible to other chemotherapeutic agents. This and the lack of overlapping toxicities with ASA404 and docetaxel make a compelling case for combination cancer treatment.